DNA Repair in Cancer Therapy

Cancer Cisplatin Radiotherapy Replication Ubiquitin DNA repair DNA damage Xeroderma pigmentosum Inhibitors Signal Transduction Drug Resistance Fanconi Anemia DNA polymerases Reactive Oxygen Species Cognitive Dysfunction Chemical biology Recombination Targeting DNA mismatch repair Translational science Cancer stem cells Oxidative damage Synthetic lethality Damage response Anticancer agents DNA Synthesis Fludarabine Nuclease MAP kinases Myopathy Cell cycle regulation EGFR PARP Nucleotide excision repair Small molecules DNA damage response Genome instability Immune checkpoint inhibitors Ototoxicity Targeted therapy Cardiotoxicity Checkpoints alternative NHEJ Base excision repair apurinic apyrimidinic endonuclease 1 BRCAness canonical NHEJ chemo-potentiation chemotherapy-induced DNA damage CHK1 Chemosensitization chemotherapy-induced peripheral neuropathy DNA double-strand break repair Chain Termination Double-strand break repair classical NHEJ Glioma therapy homologous recombination inhibitors Gemcitabine genotoxic damage DSB repair interstrand crosslink DNA-damaging agents DNA replication errors microhomology-mediated NHEJ noncanonical NHEJ nucleoli O6-alkylating anticancer drugs oncogene-induced DNA damage model for cancer development O6-methylguanine-DNA methyltransferase (MGMT) Nonhomologous end joining (NHEJ) HRD signature replication stress prognostic/predictive value of MGMT Translesion synthesis MGMT promoter methylation MGMT stem cell transfer poly(ADP-ribose) polymerase RAD51 MGMT inhibitors PARP1 nucleoside analogs replication protein A repair inhibitors